Developer docs
API playgroundTry for free, no card

Search company profiles

GC Aesthetics

Full company profile

uuid00028rf

Namestring
GC Aesthetics
Legal namestring
GC Aesthetics, Ltd.
Company typeenum
Private
Founded yearint
2007
Descriptiontext

GC Aesthetics (GCA) is a privately-held Irish medical technology company that designs, manufactures, and markets silicone breast implants and complementary surgical solutions for aesthetic and reconstructive breast surgery. Founded in 2007 through the consolidation of legacy brands Nagor and Eurosilicone, the company operates from headquarters in Dublin, Ireland, with ISO-certified manufacturing facilities in Cumbernauld, Scotland and Apt, France, and has sold more than 3 million implants across 70+ countries. Its product portfolio spans core breast implant brands (PERLE, Luna XT, The Round Collection, Adora), reconstruction devices (FixNip NRI, Blossom IVTE tissue expanders), and the Puregraft fat transfer system acquired through the OPALINE Aesthetics joint venture with Bimini Health Tech, with proprietary technology including BioQ surface treatment and Emunomic dynamic gel.

The business sells B2B exclusively to board-certified plastic surgeons and hospitals through a hybrid model of direct field sales in major European markets and exclusive distribution partners in LATAM, China, and other regions, with surgeon engagement driven by platinum and diamond sponsorships at major breast surgery conferences (ISAPS, SOFCEP, Barcelona Breast Meeting) and the GCA Academy training platform. The company's GTM motion also includes an online surgeon directory, direct-to-patient content marketing, and a branded e-commerce shop for post-surgery accessories. Products are differentiated by published 10-year prospective clinical safety data, the only implant approved under the latest European Medical Device Regulation (Luna XT), and the GCA Comfort Plus lifetime warranty covering rupture, capsular contracture, and BIA-ALCL. Pricing is not publicly disclosed, and revenue figures are not released; ownership is backed by Hayfin Capital Management, with operations led by CEO Carlos Reis Pinto and an expanded board including Chairman Luigi Ferrari.

Revenue is generated through hardware sales of implants and surgical devices plus adjacent services such as the GCA Comfort Plus warranty, GCA Academy training, and the post-surgery consumer e-commerce shop. The company is pursuing a clear expansion agenda into China, deeper LATAM penetration, and US market access via the OPALINE joint venture, supported by ongoing product launches (Adora, YOUTHLY) and regulatory first-mover positioning under the European MDR.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
breast implants, medical aesthetic devices, breast reconstruction surgery, silicone implants manufacturing, plastic surgery solutions
Industry2 codes
PRIMARYHLAHADAM
Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code3 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Medical Aesthetic Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Breast Implant Sales
TypeHardware Sales
Description

Sale of silicone breast implants and medical devices to plastic surgeons and hospitals for aesthetic and reconstructive procedures

gcaesthetics.com
2Surgical Solutions Portfolio
TypeHardware Sales
Description

Sale of complementary surgical products including tissue expanders (Blossom™), wound care (Healena™), fat transfer systems (Puregraft®), and nipple reconstruction implants (FixNip™ NRI)

gcaesthetics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 13 records shown
1PERLE™
Description

Round breast implant with BioQ™ surface technology and Emunomic™ Breast Tissue Dynamic Gel.

gcaesthetics.com
+12 more records
Core offering1 text field

GC Aesthetics designs, develops, manufactures and markets silicone breast implants and complementary surgical solutions for aesthetic and reconstructive breast surgery. The portfolio spans round and anatomical implants, tissue expanders, fat transfer systems, nipple reconstruction implants, wound healing, and 3D/AR surgical planning tools, sold exclusively to board-certified plastic surgeons and hospitals across 70+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 1.5% overall revision rate at 10 years (independent study of 716 patients)
+3 more records
Product overview1 text field

GC Aesthetics® is a comprehensive medical aesthetics company offering a broad portfolio of breast implants and surgical solutions for aesthetic and reconstructive procedures. The product lineup centers on five core breast implant brands: PERLE™ (smooth round with BioQ™ technology), Luna XT™ (MDR-compliant anatomical), The Round Collection™ (textured/smooth round options), and Adora™ (micro-textured), all supported by published 10-year clinical data. The reconstruction portfolio includes FixNip™ NRI for nipple-areola reconstruction, Blossom™ IVTE tissue expander, and Puregraft® for fat transfer. Supporting tools include HydroCone™ for complication management, Eve 4.0™ 3D/AR simulation powered by Crisalix®, The Consultation Kit™, and Noa™ postoperative bra. All products are backed by the GCA Comfort Plus™ lifetime warranty and supported by the GCA Academy™ training platform. The company has evolved from its legacy Nagor and Eurosilicone brands into a unified ONE GCA identity, operating manufacturing facilities in Scotland and France with distribution across 70 countries.

Product and service11 records
1PERLE™
CategoryBreast implants
Description

Round breast implant with revolutionary BioQ™ surface technology and highly cohesive Emunomic™ Breast Tissue Dynamic Gel, featuring a unique smooth opaque surface for board-certified plastic surgeons performing aesthetic augmentation.

2Luna XT™
CategoryBreast implants
Description

First breast implant on the market under the latest Medical Device Regulation (MDR); industry-leading micro-textured anatomical implant for breast reconstruction procedures, for plastic and reconstructive surgeons.

3The Round Collection™
CategoryBreast implants
Description

Round breast implants available in microtextured and smooth surface variants, supported by 10-year safety data with four different projections from low to extra-high, for plastic surgeons performing augmentation and reconstruction.

4Adora™
CategoryBreast implants
Description

Comprehensive micro-textured breast implant designed for stability, softness, clinical confidence, and surgical versatility in breast augmentation and reconstruction.

5FixNip™ NRI
CategoryReconstruction implants
Description

Nipple-areola reconstruction implant providing a minimally invasive solution with lasting projection and natural results for women after breast reconstruction, featuring Nitinol-reinforced silicone construction.

6Blossom™ IVTE
CategoryTissue expanders
Description

Integrated Valve Tissue Expander for temporary subcutaneous implantation, requiring periodic incremental inflation with sterile saline until desired tissue is developed, for staged breast reconstruction.

7Puregraft®
CategoryFat transfer systems
Description

Autologous fat transfer system for breast augmentation and reconstruction, enabling graft preparation through dedicated filtration; part of the combined GCA/Bimini portfolio.

8Healena™
CategoryWound care
Description

Advanced wound healing solution designed to support optimal post-surgical recovery following breast surgery, for use by surgeons and patients.

9HydroCone™
CategoryPost-operative devices
Description

Post-operative device designed to minimize complications when used with all GCA® breast implants, supporting recovery and reducing adverse events.

10Eve 4.0™
CategorySurgical planning / simulation
Description

3D planning and simulation tool powered by Crisalix® providing augmented reality breast surgery planning and patient consultation support for plastic surgeons.

11Noa™
CategoryPost-surgical apparel
Description

Postoperative compression bra for recovery support following breast augmentation or reconstruction surgery.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1G&S Group (China)
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-09-01
Description

Collaboration to launch YOUTHLY brand in China, offering premium breast implant solutions including Round Collection 100% filled, PERLE, and Luna XT implants manufactured in France and UK.

media.market.us
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-26
Description

Joint venture partnership creating 'OPALINE Aesthetics' to revolutionize breast reconstruction globally. GC Aesthetics deploys Bimini's healthcare solutions outside US and Canada; Bimini commercializes selective GCA reconstruction solutions in US to complement Puregraft portfolio. Combined expertise in design, manufacturing, and reconstruction innovation.

3Grupo Venta Internacional (GVI)
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive distributor for Mexico market, collaborating on AMCPER International Congress participation and LATAM market expansion.

gcaesthetics.com
Strategic tierCoreTypeTechnology or Integration
Description

Puregraft adipose filtration system for autologous fat transfer procedures now part of combined portfolio through Bimini partnership.

Strategic tierStrategicTypeGTM or Marketing Partner
Description

GC Aesthetics is a sponsor of ISAPS, the leading professional society for aesthetic plastic surgeons globally.

Strategic tierMinorTypeOthers
Description

Partnership supporting Total Breast Reconstruction program in Italy for breast cancer survivors.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner in Chile facilitating first FixNip NRI surgery milestone in the country.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Mentor (Johnson & Johnson)
TypeBroad incumbent
Description

Johnson & Johnson's breast aesthetics business is the largest and most established silicone and saline breast implant manufacturer globally. Directly competes with GCA across implant categories, surgeon relationships, and warranty programs, with significantly greater commercial scale.

TypeBroad incumbent
Description

AbbVie division that markets Natrelle breast implants and is one of the dominant global breast implant brands. Direct competitor across the full breast aesthetic and reconstructive portfolio, with a much larger sales force and global footprint.

TypeDirect peer
Description

Public breast implant company (Motiva brand) competing head-to-head with GCA in aesthetic and reconstruction segments. Particularly aggressive in expanding US share and in innovation around smooth surfaces and ergonomix designs.

TypeDirect peer
Description

US-focused breast implant company with portfolio overlapping GCA's PERLE and Luna XT. Direct competitor in aesthetic and reconstructive surgery, focused on US market expansion and premium surgeon channels.

TypeDirect peer
Description

German-based breast implant and soft-tissue implant manufacturer. Closest European mid-sized competitor to GCA, with overlapping implant lines, reconstruction devices, and distribution across Europe, LATAM, and Asia.

TypeDirect peer
Description

French breast implant manufacturer serving European, LATAM, and select Asian markets. Directly comparable product portfolio (silicone breast implants, expanders) competing in GCA's core European markets and similar regulatory and surgeon-loyalty dynamics.

TypeEmerging player
Description

Korean medical device company expanding in breast implants and tissue regeneration. Comparable in size and product scope to GCA but with stronger APAC distribution, and emerging presence in Europe and LATAM.

TypeOthers
Description

Partner in the OPALINE Aesthetics JV; Puregraft and reconstructive solutions provider. Strategic partner and partial competitor in select reconstruction segments, especially relevant given the JV commercial structure.

TypeOthers
Description

3D/AR simulation platform powering GCA's Eve 4.0 tool. Enabling technology peer used across breast implant manufacturers; useful for comparing surgeon-engagement and digital-surgical-planning economics in the category.

10Motiva USA / Establishment Labs (US operations)
TypeRegional player
Description

US commercial arm of Establishment Labs focused on direct-to-surgeon aesthetic implant sales. Relevant as the principal disruptor in GCA's largest whitespace (US aesthetics) where GCA relies on its Bimini JV.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GC Aesthetics

Medical Aesthetic Devicesgcaesthetics.com

What GC Aesthetics does

GC Aesthetics (GCA) is a privately-held Irish medical technology company that designs, manufactures, and markets silicone breast implants and complementary surgical solutions for aesthetic and reconstructive breast surgery. Founded in 2007 through the consolidation of legacy brands Nagor and Eurosilicone, the company operates from headquarters in Dublin, Ireland, with ISO-certified manufacturing facilities in Cumbernauld, Scotland and Apt, France, and has sold more than 3 million implants across 70+ countries. Its product portfolio spans core breast implant brands (PERLE, Luna XT, The Round Collection, Adora), reconstruction devices (FixNip NRI, Blossom IVTE tissue expanders), and the Puregraft fat transfer system acquired through the OPALINE Aesthetics joint venture with Bimini Health Tech, with proprietary technology including BioQ surface treatment and Emunomic dynamic gel.

The business sells B2B exclusively to board-certified plastic surgeons and hospitals through a hybrid model of direct field sales in major European markets and exclusive distribution partners in LATAM, China, and other regions, with surgeon engagement driven by platinum and diamond sponsorships at major breast surgery conferences (ISAPS, SOFCEP, Barcelona Breast Meeting) and the GCA Academy training platform. The company's GTM motion also includes an online surgeon directory, direct-to-patient content marketing, and a branded e-commerce shop for post-surgery accessories. Products are differentiated by published 10-year prospective clinical safety data, the only implant approved under the latest European Medical Device Regulation (Luna XT), and the GCA Comfort Plus lifetime warranty covering rupture, capsular contracture, and BIA-ALCL. Pricing is not publicly disclosed, and revenue figures are not released; ownership is backed by Hayfin Capital Management, with operations led by CEO Carlos Reis Pinto and an expanded board including Chairman Luigi Ferrari.

Revenue is generated through hardware sales of implants and surgical devices plus adjacent services such as the GCA Comfort Plus warranty, GCA Academy training, and the post-surgery consumer e-commerce shop. The company is pursuing a clear expansion agenda into China, deeper LATAM penetration, and US market access via the OPALINE joint venture, supported by ongoing product launches (Adora, YOUTHLY) and regulatory first-mover positioning under the European MDR.

GC Aesthetics firmographics

Firmographics
Name
GC Aesthetics
Legal name
GC Aesthetics, Ltd.
Website
https://gcaesthetics.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

GC Aesthetics industry classification

Industry
Product category
Medical Aesthetic Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHADAM
Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Breast implants
  • Medical aesthetic devices
  • Breast reconstruction surgery
  • Silicone implants manufacturing
  • Plastic surgery solutions

Where GC Aesthetics is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices3 records

Markets served

GC Aesthetics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Breast Implant Sales: Sale of silicone breast implants and medical devices to plastic surgeons and hospitals for aesthetic and reconstructive procedures
  2. Surgical Solutions Portfolio: Sale of complementary surgical products including tissue expanders (Blossom™), wound care (Healena™), fat transfer systems (Puregraft®), and nipple reconstruction implants (FixNip™ NRI)

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

GC Aesthetics product offering

Product offering

Core offering

GC Aesthetics designs, develops, manufactures and markets silicone breast implants and complementary surgical solutions for aesthetic and reconstructive breast surgery. The portfolio spans round and anatomical implants, tissue expanders, fat transfer systems, nipple reconstruction implants, wound healing, and 3D/AR surgical planning tools, sold exclusively to board-certified plastic surgeons and hospitals across 70+ countries.

Product overview

GC Aesthetics® is a comprehensive medical aesthetics company offering a broad portfolio of breast implants and surgical solutions for aesthetic and reconstructive procedures. The product lineup centers on five core breast implant brands: PERLE™ (smooth round with BioQ™ technology), Luna XT™ (MDR-compliant anatomical), The Round Collection™ (textured/smooth round options), and Adora™ (micro-textured), all supported by published 10-year clinical data. The reconstruction portfolio includes FixNip™ NRI for nipple-areola reconstruction, Blossom™ IVTE tissue expander, and Puregraft® for fat transfer. Supporting tools include HydroCone™ for complication management, Eve 4.0™ 3D/AR simulation powered by Crisalix®, The Consultation Kit™, and Noa™ postoperative bra. All products are backed by the GCA Comfort Plus™ lifetime warranty and supported by the GCA Academy™ training platform. The company has evolved from its legacy Nagor and Eurosilicone brands into a unified ONE GCA identity, operating manufacturing facilities in Scotland and France with distribution across 70 countries.

Differentiator

Problem solved

Functional benefit

Brands

  • PERLE™: Round breast implant with BioQ™ surface technology and Emunomic™ Breast Tissue Dynamic Gel.
  • Luna XT™
  • Adora™
  • The Round Collection™
  • FixNip™ NRI
  • Puregraft®
  • Healena™
  • Blossom™ IVTE
  • Eve 4.0™
  • Noa™
  • GCA Academy™
  • GCA Comfort Plus™ Warranty
  • Total Breast Reconstruction™

Products and services

  • PERLE™ Round breast implant with revolutionary BioQ™ surface technology and highly cohesive Emunomic™ Breast Tissue Dynamic Gel, featuring a unique smooth opaque surface for board-certified plastic surgeons performing aesthetic augmentation.
  • Luna XT™ First breast implant on the market under the latest Medical Device Regulation (MDR); industry-leading micro-textured anatomical implant for breast reconstruction procedures, for plastic and reconstructive surgeons.
  • The Round Collection™ Round breast implants available in microtextured and smooth surface variants, supported by 10-year safety data with four different projections from low to extra-high, for plastic surgeons performing augmentation and reconstruction.
  • Adora™ Comprehensive micro-textured breast implant designed for stability, softness, clinical confidence, and surgical versatility in breast augmentation and reconstruction.
  • FixNip™ NRI Nipple-areola reconstruction implant providing a minimally invasive solution with lasting projection and natural results for women after breast reconstruction, featuring Nitinol-reinforced silicone construction.
  • Blossom™ IVTE Integrated Valve Tissue Expander for temporary subcutaneous implantation, requiring periodic incremental inflation with sterile saline until desired tissue is developed, for staged breast reconstruction.
  • Puregraft® Autologous fat transfer system for breast augmentation and reconstruction, enabling graft preparation through dedicated filtration; part of the combined GCA/Bimini portfolio.
  • Healena™ Advanced wound healing solution designed to support optimal post-surgical recovery following breast surgery, for use by surgeons and patients.
  • HydroCone™ Post-operative device designed to minimize complications when used with all GCA® breast implants, supporting recovery and reducing adverse events.
  • Eve 4.0™ 3D planning and simulation tool powered by Crisalix® providing augmented reality breast surgery planning and patient consultation support for plastic surgeons.
  • Noa™ Postoperative compression bra for recovery support following breast augmentation or reconstruction surgery.

Quantifiable outcome

  • 1.5% overall revision rate at 10 years (independent study of 716 patients)
  • +3 more outcomes

Companies that use GC Aesthetics

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

GC Aesthetics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature6 records

GC Aesthetics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered major, core, strategic and minor.

  • G&S Group (China)majorChannel Partner/ Reseller/ Distributor · 1 September 2024Collaboration to launch YOUTHLY brand in China, offering premium breast implant solutions including Round Collection 100% filled, PERLE, and Luna XT implants manufactured in France and UK.
  • Bimini Health TechcoreStrategic or Co-development Partner · 26 October 2023Joint venture partnership creating 'OPALINE Aesthetics' to revolutionize breast reconstruction globally. GC Aesthetics deploys Bimini's healthcare solutions outside US and Canada; Bimini commercializes selective GCA reconstruction solutions in US to complement Puregraft portfolio. Combined expertise in design, manufacturing, and reconstruction innovation.
  • Grupo Venta Internacional (GVI)majorChannel Partner/ Reseller/ DistributorExclusive distributor for Mexico market, collaborating on AMCPER International Congress participation and LATAM market expansion.
  • Puregraft (Bimini subsidiary)coreTechnology or IntegrationPuregraft adipose filtration system for autologous fat transfer procedures now part of combined portfolio through Bimini partnership.
  • ISAPS (International Society of Aesthetic Plastic Surgery)strategicGTM or Marketing PartnerGC Aesthetics is a sponsor of ISAPS, the leading professional society for aesthetic plastic surgeons globally.
  • Komen ItaliaminorOthersPartnership supporting Total Breast Reconstruction program in Italy for breast cancer survivors.
  • Medicorp (Chile)majorChannel Partner/ Reseller/ DistributorDistribution partner in Chile facilitating first FixNip NRI surgery milestone in the country.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

GC Aesthetics competitors and assessment

Company assessment

Broad incumbents

  • Mentor (Johnson & Johnson): Johnson & Johnson's breast aesthetics business is the largest and most established silicone and saline breast implant manufacturer globally. Directly competes with GCA across implant categories, surgeon relationships, and warranty programs, with significantly greater commercial scale.
  • Allergan Aesthetics (AbbVie): AbbVie division that markets Natrelle breast implants and is one of the dominant global breast implant brands. Direct competitor across the full breast aesthetic and reconstructive portfolio, with a much larger sales force and global footprint.

Direct peers

  • Establishment Labs: Public breast implant company (Motiva brand) competing head-to-head with GCA in aesthetic and reconstruction segments. Particularly aggressive in expanding US share and in innovation around smooth surfaces and ergonomix designs.
  • Sientra: US-focused breast implant company with portfolio overlapping GCA's PERLE and Luna XT. Direct competitor in aesthetic and reconstructive surgery, focused on US market expansion and premium surgeon channels.
  • POLYTECH Health & Aesthetics: German-based breast implant and soft-tissue implant manufacturer. Closest European mid-sized competitor to GCA, with overlapping implant lines, reconstruction devices, and distribution across Europe, LATAM, and Asia.
  • Sebbin: French breast implant manufacturer serving European, LATAM, and select Asian markets. Directly comparable product portfolio (silicone breast implants, expanders) competing in GCA's core European markets and similar regulatory and surgeon-loyalty dynamics.

Emerging players

  • HansBiomed: Korean medical device company expanding in breast implants and tissue regeneration. Comparable in size and product scope to GCA but with stronger APAC distribution, and emerging presence in Europe and LATAM.

Others

  • Bimini Health Tech: Partner in the OPALINE Aesthetics JV; Puregraft and reconstructive solutions provider. Strategic partner and partial competitor in select reconstruction segments, especially relevant given the JV commercial structure.
  • Crisalix: 3D/AR simulation platform powering GCA's Eve 4.0 tool. Enabling technology peer used across breast implant manufacturers; useful for comparing surgeon-engagement and digital-surgical-planning economics in the category.

Regional players

  • Motiva USA / Establishment Labs (US operations): US commercial arm of Establishment Labs focused on direct-to-surgeon aesthetic implant sales. Relevant as the principal disruptor in GCA's largest whitespace (US aesthetics) where GCA relies on its Bimini JV.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

GC Aesthetics social profiles

Digital presence

GC Aesthetics compliance and trust

Trust signal

Compliance6 records

GC Aesthetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GC Aesthetics leadership team

Management profile

Number of profiles

Profiles13 records

GC Aesthetics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

GC Aesthetics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GC Aesthetics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GC Aesthetics

What does GC Aesthetics do?

GC Aesthetics designs, develops, manufactures and markets silicone breast implants and complementary surgical solutions for aesthetic and reconstructive breast surgery. The portfolio spans round and anatomical implants, tissue expanders, fat transfer systems, nipple reconstruction implants, wound healing, and 3D/AR surgical planning tools, sold exclusively to board-certified plastic surgeons and hospitals across 70+ countries.

Is GC Aesthetics a public or private company?

GC Aesthetics is a private company. It is classified as private equity controlled and is currently operating.

When was GC Aesthetics founded?

GC Aesthetics was founded in 2007. It employs 251 to 500 people.

Where is GC Aesthetics based?

GC Aesthetics is headquartered in Dublin, Ireland, in the Europe region.

How does GC Aesthetics make money?

Two revenue lines are on record. Breast Implant Sales are the primary driver. The others are surgical Solutions Portfolio.

Who are GC Aesthetics's main competitors?

Broad incumbents on record are Mentor (Johnson & Johnson) and Allergan Aesthetics (AbbVie). Direct peers are Establishment Labs, Sientra, POLYTECH Health & Aesthetics and Sebbin. HansBiomed is listed as an emerging player. Others are Bimini Health Tech and Crisalix. Motiva USA / Establishment Labs (US operations) is listed as a regional player.

Does GC Aesthetics have an API?

No public API is recorded for GC Aesthetics.

What industry is GC Aesthetics in?

GC Aesthetics's product category is Medical Aesthetic Devices. Its primary akta.pro industry code is HLAHADAM, Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits), with a secondary code of HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FortunebusinessinsightsSurgical Cosmetic Procedures Market Size, Share [2034]The global surgical cosmetic procedures market was valued at USD 46.94 billion in 2025 and is expected to grow to USD 62.84 billion by 2034, with a CAGR of 3.30%. North America dominated the market, with key players including Johnson & Johnson, GC Aesthetics, and Establishment Labs focusing on new product launches and strategic expansions.openPR.comBreast Aesthetic Surgery Market (2026) | Silicone Implants, Fat Grafting, Body Contouring & Growth Drivers | Top Companies 2026 - Alma Lasers, Mentor Worldwide LLC, GC Aesthetics plc, Aesthetics GmbHDataM Intelligence released a market research report on the Breast Aesthetic Surgery Market, projecting growth at a CAGR of 8.5% between 2024 and 2031, driven by technological advancements in breast implant technologies, rising consumer acceptance of cosmetic procedures, and expanding adoption of minimally invasive techniques. Key industry developments include Allergan expanding its breast implant portfolio with enhanced safety features, Mentor Worldwide introducing next-generation implants, and several strategic mergers and acquisitions by GC Aesthetics, Establishment Labs, and Allergan Aesthetics to strengthen market positioning. The report identifies North America as the leading regional market, with Asia-Pacific showing rapid growth due to rising medical tourism and disposable incomes.openPR.comAnalysis of Key Market Segments Influencing the Cosmetic Implants IndustryThe cosmetic implants market is forecast to reach $17.56 billion by 2030, growing at a 7.3% CAGR, driven by rising demand for cosmetic procedures, medical tourism expansion, and innovations in bioengineered implant materials. In August 2023, Bimini Health Tech acquired Ideal Implants Inc., a US-based manufacturer of cosmetic implants including breast implants, to broaden its portfolio in plastic and reconstructive surgery globally. In July 2024, GC Aesthetics, a France-based manufacturer, introduced its Luna XT and PERLE breast implant products in Hainan, China, featuring advanced microtextured surfaces and bioengineered dynamic gel technology.openPR.comAnalysis of Key Market Segments Driving the Aesthetic Implants MarketThe Business Research Company published a market report projecting the global aesthetic implants market will reach $7.82 billion by 2030, growing at a compound annual growth rate of 6.8%, driven by demand for cosmetic procedures and technological innovations. In May 2023, Henry Schein, Inc. acquired the Brazil-based S.I.N. Implant System to expand its presence in the dental implant market, targeting emerging economies. In April 2024, GC Aesthetics launched LUNA XT, the world's first micro-textured anatomical breast implant approved under the European Medical Device Regulation.Cosmetics BusinessIreland's GC Aesthetics raises $20m in fundingGC Aesthetics raised $20m in Series D financing from existing investors. The company, which manufactures over 325,000 breast implants annually, will use the funds to expand commercial operations and invest in product innovation and customer service. It aims to become the leading breast implant company selling outside the US.FortunebusinessinsightsU.S. Breast Implants Market Size, ShareThe U.S. breast implants market was valued at USD 1.08 billion in 2022 and is projected to grow at a CAGR of 7.4% through 2030, driven by rising breast augmentation procedures, increasing mastectomy rates due to breast cancer, and new product launches. Key industry players including GC Aesthetics, AbbVie Inc., Johnson & Johnson Services Inc., and Sientra, Inc. are focusing on product innovation and strategic collaborations to expand their market share. In October 2021, the U.S. FDA updated safety requirements for breast implants, restricting sales and distribution to ensure patients consider potential risks, which may act as a restraining factor on market growth.Precedence ResearchMedical Aesthetic Treatments Market Size, Report by 2034The global medical aesthetic treatments market is projected to grow significantly from 2025 to 2034, driven by rising demand for minimally invasive procedures, technological advancements, and increasing social acceptance of cosmetic treatments. North America led the market in 2024 with a 38% share, while Asia Pacific is expected to be the fastest-growing region over the forecast period. Key industry developments include Allergan Aesthetics' FDA approval of SKINVIVE by JUVÉDERM for cheek skin smoothness, GC Aesthetics' launch of the MDR-approved LUNA xt Anatomical Breast Implant, and Healthcare Holding Schweiz AG's acquisition of Aestheticbedarf AG to expand its Medical Beauty platform in Switzerland.Market ScoopAsia Pacific Medical Aesthetics Market to Grow 14.1% AnnuallyThe Asia Pacific medical aesthetics market is projected to grow from USD 4.8 billion in 2024 to USD 17.9 billion by 2034, representing a CAGR of 14.1%, driven by rising middle-class incomes, urbanization, and growing demand for non-invasive procedures. Facial aesthetics hold the largest application share at 45.1%, while injectables lead the procedure type segment at 41.7%. GC Aesthetics launched its YOUTHLY brand in China in September 2024 in collaboration with G&S Group, offering premium breast implant solutions manufactured in France and the UK.Mpo-magGC Aesthetics Welcomes Two New Board MembersGC Aesthetics appointed Luigi Ferrari as non-executive board chairman and Patrick Lee as a board director, following a renewed partnership with Hayfin Capital Management. The company has sold over 3 million implants across 70 countries, with products supported by 10-year clinical data.